NCT05125640View on ClinicalTrials.gov

Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 13, 2019

Primary Completion Date

January 7, 2020

Study Completion Date

January 7, 2020

Conditions

Pharmacokinetics

Interventions

DRUG

"Progesterone 200 mg Soft Capsule (JSC Farmak, Ukraine)"

Orally, with 240 mL of water at dosing in sitting position

DRUG

Utrogestan® 200 mg Soft Capsule (Manufacturer by: Cyndea Pharma, S.L., Spain, MAH: Laboratoires Besins International, France)

Orally, with 240 mL of water at dosing in sitting position

Trial Locations (1)

11910

Arab Pharmaceutical Industry Consulting/Pharmaceutical Research Unit, Amman

All Listed Sponsors

lead

"Joint Stock Company Farmak"

INDUSTRY

NCT05125640 - Fasting Bioequivalence Study of 2 Oral Progesterone Soft Capsules 200 mg in 48 Healthy Female Subjects | Biotech Hunter | Biotech Hunter